Loading
Cue Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Jan 2026.
Cue Biopharma, Inc.: what insiders have been doing
This page follows insider dealings at Cue Biopharma, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 34 filings were filed, from 11 insiders.
Both sides are active: 1 purchase worth €1,111 and 15 sales worth €2.1M, from 1 insider and 3 insiders respectively. Netting one side against the other leaves €2.1M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 senior executive among the declarants. At €800k, the sale published on 14 August 2026 by Lin Shao-Lee is the largest of the period (0.40% of market cap).
The last insider purchase was made public on 2 January 2026, 289 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 34 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 8 purchases and 15 sales.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
53
Thresholds
n/a
Buy Volume
€4M
8 ops. · all time
Sell Volume
€2M
15 ops. · all time
Who traded when
BuySaleShao-Lee Lin7 sales
Michael Vincent Meluzio4 sales
Sumita Ray4 sales
Pasha Sarraf1 buy
Passeri Daniel R1 buy
Since the insiders bought
- -53.8%Entry US$11.49 · Close at T+90 US$5.31
- +9.7%Entry US$111.00 · Close at T+365 US$121.80
- +9.2%Entry US$107.40 · Close at T+365 US$117.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cue Biopharma, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$88.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.57
Analyst consensus
3 analystsStrong buy
US$66.00Target US$88.00(+350%)US$115.00
Income statement
RevenueUS$27.5M
EBITDA-US$22.3M-81% margin
Net income-US$26.6M-96.9% margin
Valuation
P/Book44.3x
Beta2.63
Balance sheet & cash
Market capUS$142.2M
Total debtUS$4.2M
Free Cash Flow-US$21.9M
Debt / Equity133%
Profitability & ownership
ROE-1603.5%
ROA-172.7%
% insiders15.2%
% institutions22.8%
Last declaration on 14 October 2026
Declarations53 total
1,844 shares@ US$28.05Common StockSEC:0001579629-26-000012:0
1,144 shares@ US$28.05Common StockSEC:0002138368-26-000009:0
10,000 shares@ US$27.50Common StockSEC:0001725092-26-000019:0
1,087 shares@ US$28.05Common StockSEC:0001725092-26-000019:1
1,844 shares@ US$28.050.036% mcap16.7% of flowCommon StockSEC144:0001579629-26-000010
11,087 shares@ US$27.55390.21% mcap16.5% of flowCommon StockSEC144:0001725092-26-000017
18,400 shares0Common StockSEC:0002059447-26-000006:0
18,900 shares0Common StockSEC:0001974756-26-000006:0
13,647 shares0Common StockSEC:0002138368-26-000007:0
18,196 shares0Common StockSEC:0001579629-26-000008:0
2,383 shares@ US$29.370.030% mcap26.3% of flowCommon StockSEC:0001579629-26-000008:1
4,106 shares@ US$30.350.054% mcap73.6% of flowCommon StockSEC:0002138368-26-000007:2
3 shares@ US$31.130.0000% mcap0.1% of flowCommon StockSEC:0002138368-26-000007:3
6,442 shares@ US$30.350.085% mcap73.6% of flowCommon StockSEC:0001579629-26-000008:2
4 shares@ US$31.130.0001% mcap0.0% of flowCommon StockSEC:0001579629-26-000008:3
1,519 shares@ US$29.370.019% mcap26.3% of flowCommon StockSEC:0002138368-26-000007:1
58,258 shares@ US$27.40170.69% mcap100.0% of flowCommon StockSEC144:0001725092-26-000011
109,179 shares0Common StockSEC:0001725092-26-000013:0
34,225 shares@ US$26.990.40% mcap57.5% of flowCommon StockSEC:0001725092-26-000013:1
5,775 shares@ US$27.750.069% mcap10.0% of flowCommon StockSEC:0001725092-26-000013:2
5,423 shares@ US$27.190.064% mcap9.2% of flowCommon StockSEC:0001725092-26-000013:3
2,375 shares@ US$28.110.029% mcap4.2% of flowCommon StockSEC:0001725092-26-000013:4
10,460 shares@ US$29.480.13% mcap19.2% of flowCommon StockSEC:0001725092-26-000013:5
8,829 shares@ US$30.140.12% mcap100.0% of flowCommon StockSEC144:0001579629-26-000006
25,500 shares0Common StockSEC:0001320383-26-000006:0
25 of 53 declarations
About Cue Biopharma, Inc.
Cue Biopharma, Inc. is a U.S.-listed clinical-stage biopharmaceutical company traded on the Nasdaq in the United States, focused on developing therapeutic biologics that selectively engage and modulate disease-specific T cells. From an investor’s perspective, the company sits squarely in the healthcare/pharma segment, with a high-risk, high-upside profile typical of platform-driven biotech names. It was founded in December 2014 and built around research originating from the laboratory of Dr. Steven Almo at Albert Einstein College of Medicine. A foundational licensing agreement with Einstein, signed in January 2015, granted key patent rights supporting Cue’s core technology base. The company’s corporate headquarters are in Boston, Massachusetts.
Cue’s central asset is its proprietary Immuno-STAT® platform (Selective Targeting and Alteration of T cells), designed to target disease-relevant T cells with greater precision than conventional broad immune-modulating approaches. The strategic goal is to create injectable biologics that can enhance efficacy while limiting off-target immune effects. Over time, Cue has developed a pipeline spanning oncology and immune-mediated disease, but the company’s messaging and recent execution have increasingly emphasized autoimmune and inflammatory disorders as the main value-creation opportunity.
Read moreShow less
The most important development in 2025-2026 is CUE-401, which management describes as the company’s lead autoimmune asset and a program being advanced toward IND readiness. This is an important signal for investors because it indicates a pipeline re-centering around a differentiated lead candidate rather than a broad early-stage portfolio. Cue also expanded its strategic options through partnerships: it announced a collaboration and license agreement with ImmunoScape aimed at a solid-tumor cell therapy approach, and it entered into an exclusive license agreement with Ascendant Health Sciences for a dual-mechanism anti-IgE antibody. These deals suggest a willingness to monetize technology, diversify risk, and support development through external capital and collaborations.
Commercially, Cue remains a pre-revenue or limited-revenue biotech in the traditional sense, with collaboration revenue playing a meaningful role in recent financial reporting. The company continues to rely on external financing to fund R&D and operations, which is consistent with a development-stage biotech that has not yet reached product commercialization. Competitively, Cue is a niche player relative to large multinational immunology and oncology companies. Its potential advantage lies in the uniqueness of the Immuno-STAT platform and the possibility of generating highly targeted therapies with improved tolerability. For international equity investors, CUE on the Nasdaq in the United States is best viewed as a speculative clinical biotech story driven by pipeline execution, partnership optionality, and upcoming regulatory milestones.
